The tweet was deleted by the author.
But we saved everything 🙂.
Cullinan Therapeutics released its corporate update and reported financial results for the third quarter of 2026. The company also provided an overview of upcoming milestones across its T cell engager pipeline.
The announcement signals the firm's continued efforts to advance its immuno-oncology programs. Full details are available through the official company update.
View post on X Loading...
Cullinan Therapeutics recently shared new clinical data from its Genrix Phase 1b 2a study of velinotamig for SLE at the ACR26 conference, according to a company update (link). Earlier, the firm received FDA and TGA clearance to initiate a global Phase 1 2 study of velinotamig in autoimmune blood disorders (link). These developments reflect the company’s active clinical pipeline.